XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities:    
Net income (loss) $ 4,413,702 $ (1,054,601)
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Non-cash acquired in-process research and development 0 87,749
Share-based compensation 152,903 192,504
Change in fair value of investments 63,880 53,277
Change in fair value of debt and liability instruments 85,376 90,032
Gain on deconsolidation of subsidiaries (17,354) (29,276)
Gain on sale of Telavant net assets (5,348,410) 0
Depreciation and amortization 16,811 12,904
Non-cash lease expense 5,047 6,009
Other (31,846) (8,066)
Changes in assets and liabilities, net of effects from acquisition and divestiture:    
Other current assets (18,767) (31,037)
Accounts payable 1,797 13,970
Accrued expenses (15,785) 5,702
Operating lease liabilities (6,151) (6,814)
Other 41,986 3,342
Net cash used in operating activities (656,811) (664,305)
Cash flows from investing activities:    
Milestone payments 0 (140,136)
Purchase of property and equipment (1,033) (11,068)
Proceeds from sale of subsidiary interests 47,500 0
Proceeds from sale of Telavant net assets, net 5,233,396 0
Cash decrease upon deconsolidation of subsidiaries (83,679) (6,706)
Other 511 88
Net cash provided by (used in) investing activities 5,196,695 (157,822)
Cash flows from financing activities:    
Proceeds from issuance of the Company's common shares, net of issuance costs paid 199,822 94,735
Proceeds from issuance of subsidiary common shares, net of issuance costs paid 238,733 67,727
Proceeds from subsidiary debt financings, net of financing costs paid 0 159,899
Payment of subsidiary dividend (6,000) 0
Repayment of debt by subsidiary (21,815) (22,108)
Payment of offering costs and loan origination costs 0 (2,250)
Payments on principal portion of finance lease obligations (1,225) 0
Proceeds from exercise of the Company's and subsidiary stock options 51,023 569
Taxes paid related to net settlement of equity awards (9,101) (9,442)
Proceeds from issuance of the Company's common shares under employee stock purchase plan 587 0
Proceeds from exercise of the Company's warrants 5 0
Payment for redemptions of the Company's warrants (41) 0
Net cash provided by financing activities 451,988 289,130
Effect of exchange rate changes on cash, cash equivalents, and restricted cash 1,471 0
Net change in cash, cash equivalents and restricted cash 4,993,343 (532,997)
Cash, cash equivalents and restricted cash at beginning of period 1,692,115 2,074,034
Cash, cash equivalents and restricted cash at end of period 6,685,458 1,541,037
Non-cash investing and financing activities:    
Cashless exercise of the Company's warrants 83,258 0
Issuance of the Company's common shares and other consideration for an acquisition 0 9,694
Other $ 301 $ 7,063